PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8656342-4	1995	Using this new index, there was a little difference in beta-1 selectivity between acebutolol and pindolol (3.1:1.0), in contrast to a marked difference in beta-1 selectivity (320:1) as a conventional index between these two drugs.	Acebutolol	82-92	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	55-61	
9213947-0	1997	[Doppler echocardiography in assessing the effect of the beta 1-selective adrenoblocker acebutolol on left-ventricular diastolic filling in hypertension patients].	Acebutolol	88-98	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	57-63	
2883876-2	1987	Comparisons between nonselective beta-blocking agents, such as propranolol and nadolol, with beta 1-selective drugs, such as metoprolol, atenolol and acebutolol, have demonstrated close similarities in their antihypertensive effects in patients.	Acebutolol	150-160	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	93-99	
3392240-1	1988	Acebutolol, a beta-1 selective beta blocker with intrinsic sympathomimetic activity has been shown to be an effective agent in chronic angina pectoris therapy, with twice or three times daily dosing.	Acebutolol	0-10	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	14-20	
2883878-3	1987	However, patients with chest problems may be treated effectively with beta 1-selective drugs, including acebutolol, atenolol and metoprolol.	Acebutolol	104-114	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	70-76	
7259364-7	1981	Under the experimental conditions of this trial, propranolol inhibited beta 1 and beta 2 receptors at the same time, whereas acebutolol inhibited only beta 1 receptors.	Acebutolol	125-135	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	151-157	
3699050-2	1986	We investigated the effect on serum K of intravenous acebutolol (a relatively beta 1-selective agent) in 50 patients with AMI.	Acebutolol	53-63	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	78-84	
3699050-8	1986	We conclude that the administration of intravenous acebutolol after AMI raises serum K, despite the fact that this beta receptor blocking agent is relatively beta 1-selective.	Acebutolol	51-61	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	158-164	
6756931-11	1982	The ventilatory and haemodynamic findings suggest a lower degree of beta 1-selectivity after oral administration of acebutolol as compared to metoprolol.	Acebutolol	116-126	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	68-74	
2878632-3	1986	The beta 1-antagonist with intrinsic sympathicomimetic activity (ISA) acebutolol (200 mg) and the beta 1-antagonist metoprolol (50 mg) did not influence the fall in systolic pressure either, despite a significant decrease in supine and standing heart rates and disappearance of increase in heart rate on standing up.	Acebutolol	70-80	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	4-10	
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Acebutolol	195-205	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	25-31	
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Acebutolol	195-205	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	84-90